IDiyas

For the Inventor, By the Inventor

Villemoisson-sur-Orge, France

Yves Ribeill

USPTO Granted Patents = 9

Average Co-Inventor Count = 8.5

ph-index = 3

Forward Citations = 35(Granted Patents)


Location History:

  • Thiais, FR (1995)
  • Villemoisson Sur Orge, FR (1998 - 2000)

Company Filing History:

goldMedal9 out of 247 
 
Rhone-poulenc Rorer S.a.
 patents

Years Active: 1995-2000

Loading Chart...
9 patents (USPTO):Explore Patents
1. 6057454 - 1-oxo-1H-inden-2-yl-1H-imidazole-2-carboxylic acid intermediates (2000-05-02),
2. 5922716 - 5H-indeno�1,2-b!pyrazine-2,3-dione derivatives, their preparation and (1999-07-13),
3. 5902803 - 5H,10H-imidazo�1,2-a!indeno�1,2-e!pyrazin-4-one derivatives, preparation (1999-05-11),
4. 5807859 - Imidazo (1,2-A)-Indeno (1,2-E) pyrazin-4-one derivatives and (1998-09-15),
5. 5789406 - Indeno�1,2-E!pyrazine-4-ones, their preparation and the medicaments (1998-08-04),
6. 5777114 - Spiro�heterocycle-imidazo�1,2-a!indeno�1,2-e!pyrazine!-4'-ones, (1998-07-07),
7. 5753657 - Imidazo�1,2-A! pyrazine-4-one, preparation thereof and drugs containing (1998-05-19),
8. 5726175 - Imidazo�1,2-A!indeno�1,2-E!pyrazine-2-carboxylic acid derivatives, (1998-03-10),
9. 5468888 - Lupane derivatives, their preparation and the pharmaceutical (1995-11-21),

Title: Yves Ribeill: Innovator in Pharmacological Compounds

Introduction

Yves Ribeill is a notable inventor based in Villemoisson-sur-Orge, France. He has made significant contributions to the field of pharmacology, holding a total of nine patents. His work focuses on the development of compounds with valuable pharmacological properties.

Latest Patents

One of Yves Ribeill's latest patents involves the synthesis of 1-oxo-1H-inden-2-yl-1H-imidazole-2-carboxylic acid intermediates. This compound, represented by a specific formula, includes various radicals that can be utilized to prepare other compounds with significant pharmacological effects. These compounds act as antagonists of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor and are also non-competitive antagonists of the N-methyl-D-aspartate (NMDA) receptor. The implications of these compounds are profound, as they serve as ligands for NMDA receptor glycine modulator sites.

Career Highlights

Yves Ribeill has had a distinguished career, primarily working with Rhone-Poulenc Rorer S.A. His innovative research has led to advancements in the understanding and treatment of various neurological conditions through the development of new pharmacological agents.

Collaborations

Throughout his career, Yves has collaborated with esteemed colleagues such as Jean-Claude Aloup and Dominique Damour. These partnerships have fostered a collaborative environment that enhances the innovation process.

Conclusion

Yves Ribeill's contributions to pharmacology through his patents and collaborations highlight his role as a significant inventor in the field. His work continues to influence the development of new therapeutic agents that may improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…